Claims for Patent: 5,629,198

Summary for Patent: 5,629,198

Title:	Anti-HIV agent
Abstract:	The invention relates to an anti-HIV agent comprising, as an active ingredient, at least one porphyrin derivative selected from the following derivatives (A) and (B): (A) porphyrins modified with a compound selected from carbodiimides, alkylenediamines and alcohols; and (B) complexes of a plasma protein or a chemically modified plasma protein and a porphyrin which may have been modified with a compound selected from carbodiimides, alkylenediamines and alcohols. This anti-HIV agent is excellent in killing effect on HIV-infected cells, inhibitory effect on cytopathy due to HIV infection and HIV-replication inhibiting effect, and high in safety.
Inventor(s):	Mizumoto; Kenji (Odawara, JP), Tsuboi; Hiroshi (Odawara, JP), Miyajima; Hideki (Odawara, JP), Fujimoto; Hiroshi (Odawara, JP), Ajisaka; Katsumi (Odawara, JP), Fujiki; Yukio (Odawara, JP), Tsunoo; Hajime (Odawara, JP)
Assignee:	Meiji Milk Products Co., Ltd. (Tokyo, JP)
Application Number:	08/175,438
Patent Claims:	1. A method of killing HIV-infected cells in vitro which comprises administering an effective amount of a porphyrin derivative to HIV-infected cells in vitro, wherein said porphyrin derivative is the reaction product of a porphyrin compound and a carbodiimide compound; said porphyrin compound having a carboxyl terminated side chain at the 13 or 17 positions of said porphyrin compound, said carboxyl group including a carbonyl carbon atom; and said carbodiimide compound having a carbon atom double bonded to two nitrogen atoms which are reactable with said carboxyl group whereby said nitrogen atom of said carbodiimide compound is chemically bonded to said porphyrin compound via a chemical bond between said nitrogen atom and carbonyl carbon atom. 2. The method as claimed in claim 1, wherein the porphyrin is a compound selected from the group consisting of hemin, protoporphyrin, mesoporphyrin, iron mesoporphyrin, hematoporphyrin, iron hematoporphyrin, deuteroporphyrin, copper chlorophyllin and a physiologically acceptable salt of said porphyrin. 3. The method as claimed in claim 1, wherein the carbodiimide is a compound selected from the group consisting of N,N'-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), 1-cyclohexyl-3-(3-dimethylaminopropyl)carbodiimide (CDC), 1-isopropyl-3-(3-dimethylaminopropyl)-carbodiimide (IDC), and 1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide (CMC). 4. The method as claimed in claim 1, wherein the porphyrin is a hemin and the carbodiimide is 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. 5. A method of killing HIV-infected cells in vitro which comprises administering an effective amount of a complex of a plasma protein or a chemically modified plasma protein and a porphyrin derivative to HIV-infected cells in vitro, wherein said chemically modified plasma protein is a protein obtained by a modification whereby polarity of the amino acid side chain is made negative(-), and said porphyrin derivative is the reaction product of a porphyrin compound and a carbodiimide compound; said porphyrin compound having a carboxyl terminated side chain at the 13 or 17 positions of said porphyrin compound, said carboxyl group including a carbonyl carbon atom; and said carbodiimide compound having a carbon atom double bonded to two nitrogen atoms which are reactable with said carboxyl group whereby said nitrogen atom of said carbodiimide compound is chemically bonded to said porphyrin compound via a chemical bond between said nitrogen atom and carbonyl carbon atom. 6. The method claimed in claim 5, wherein the plasma protein is a protein selected from the group consisting of human serum albumin, human immunoglobulin, human transferrin, human fibrinogen and bovine serum albumin. 7. The method claimed in claim 5, wherein the chemically modified plasma protein is a succinylated or maleylated plasma protein. 8. The method as claimed in claim 5, wherein the porphyrin is a compound selected from the group consisting of hemin, protoporphyrin, mesoporphyrin, iron mesoporphyrin, hematoporphyrin, iron hematoporphyrin, deuteroporphyrin, copper chlorophyllin and a physiologically acceptable salt of said porphyrin. 9. The method as claimed in claim 5, wherein the carbodiimide is a compound selected from the group consisting of N,N'-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), 1-cyclohexyl-3-(3-dimethylaminopropyl)carbodiimide (CDC), 1-isopropyl-3-(3-dimethylaminopropyl)-carbodiimide (IDC), and 1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide (CMC). 10. The method claimed in claim 5, wherein the chemically modified plasma protein is a succinylated human serum albumin, the porphyrin is a hemin, and the carbodiimide is 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. 11. The method as claimed in claim 5, wherein the porphyrin compound is S-HSA-EDC-Hemin, IDC-Hemin, S-HSA-IDC-Hemin, or EDC-Hemin. 12. A composition for killing HIV-infected cells which comprises an effective amount of a porphyrin derivative wherein said porphyrin derivative is the reaction product of a porphyrin compound and a carbodiimide compound; said porphyrin compound having a carboxyl terminated side chain at the 13 or 17 positions of said porphyrin compound, said carboxyl group including a carbonyl carbon atom; and said carbodiimide compound having a carbon atom double bonded to two nitrogen atoms which are reactable with said carboxyl group whereby said nitrogen atom of said carbodiimide compound is chemically bonded to said porphyrin compound via a chemical bond between said nitrogen atom and carbonyl carbon atom. 13. The composition as claimed in claim 12, wherein the porphyrin is a compound selected from the group consisting of hemin, protoporphyrin, mesoporphyrin, iron mesoporphyrin, hematoporphyrin, iron hematoporphyrin, deuteroporphyrin, copper chlorophyllin and a physiologically acceptable salt of said porphyrin. 14. The composition as claimed in claim 12, wherein the carbodiimide is a compound selected from the group consisting of N,N'-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), 1-cyclohexyl-3-(3-dimethylaminopropyl)carbodiimide (CDC), 1-isopropyl-3-(3-dimethylaminopropyl)-carbodiimide (IDC), and 1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide (CMC). 15. The composition claimed in claim 12, wherein the porphyrin is a hemin and the carbodiimide is 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. 16. A composition for killing HIV-infected cells which comprises a carrier and an effective amount of a complex of a plasma protein or a chemically modified plasma protein and a porphyrin derivative, wherein said chemically modified plasma protein is a protein obtained by a modification whereby polarity of the amino acid side chain is made negative(-), and said porphyrin derivative is the reaction product of a porphyrin compound and a carbodiimide compound; said porphyrin compound having a carboxyl terminated side chain at the 13 or 17 positions of said porphyrin compound, said carboxyl group including a carbonyl carbon atom; and said carbodiimide compound having a carbon atom double bonded to two nitrogen atoms which are reactable with said carboxyl group whereby said nitrogen atom of said carbodiimide compound is chemically bonded to said porphyrin compound via a chemical bond between said nitrogen atom and carbonyl carbon atom. 17. The composition claimed in claim 16, wherein the plasma protein is a protein selected from the group consisting of human serum albumin, human immunoglobulin, human transferrin, human fibrinogen and bovine serum albumin. 18. The composition claimed in claim 16, wherein the chemically modified plasma protein is a succinylated or maleylated plasma protein. 19. The composition as claimed in claim 16, wherein the porphyrin is a compound selected from the group consisting of hemin, protoporphyrin, mesoporphyrin, iron mesoporphyrin, hematoporphyrin, iron hematoporphyrin, deuteroporphyrin, copper chlorophyllin and a physiologically acceptable salt of said porphyrin. 20. The composition as claimed in claim 16, wherein the carbodiimide is a compound selected from the group consisting of N,N'-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), 1-cyclohexyl-3-(3-dimethylaminopropyl)carbodiimide (CDC), 1-isopropyl-3-(3-dimethylaminopropyl)-carbodiimide (IDC), and 1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide (CMC). 21. The composition as claimed in claim 16, wherein the chemically modified plasma protein is a succinylated human serum albumin, the porphyrin is a hemin, and the carbodiimide is 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. 22. The composition as claimed in claim 16, wherein the porphyrin compound is S-HSA-EDC-Hemin, IDC-Hemin, S-HSA-IDC-Hemin, or EDC-Hemin. 23. The method of claim 1 wherein the porphyrin compound has a carboxyl terminated side chain at the 13 and 17 positions of said porphyrin compound. 24. The method of claim 5 wherein the porphyrin compound has a carboxyl terminated side chain at the 13 and 17 positions of said porphyrin compound. 25. The composition of claim 12 wherein the porphyrin compound has a carboxyl terminated side chain at the 13 and 17 positions of said porphyrin compound. 26. The composition of claim 16 wherein the porphyrin compound has a carboxyl terminated side at the 13 and 17 position of said porphyrin compound.

Details for Patent 5,629,198

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2014-05-13
Recordati Rare Diseases, Inc.	PANHEMATIN	hemin for injection	For Injection	101246	07/20/1983		2014-05-13
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2014-05-13
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2014-05-13
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2014-05-13
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2014-05-13
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	06/11/2003		2014-05-13